|
Overview |
Product information |
Accredo services |
Contact team
Xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
Xolair is the first humanized therapeutic antibody for the treatment of asthma and the first approved therapy designed to target the antibody IgE, a key underlying cause of the symptoms of allergic asthma.
For more information on Xolair, please visit Xolair.com, or download the full prescribing information.
Xolair is a registered trademark of Genentech, Inc.
| 
